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Introduction
H
epatitis C virus (HCV) is a major cause of liver-
related morbidity and mortality worldwide 
and represents a major public health problem (1-6). 
HCV can spread parenterally through contact with 
infected  blood,  transfusion  of  infected  blood  and 
its products, intravenous drug use, contamination 
during medical procedures, and a lack of attention 
to health precautions. Despite a declining incidence 
of new infections (7, 8), the burden of the disease, 
both in terms of mortality and cost, is expected to 
increase over the next decade, and HCV infection 
will maintain to be a potential cause of morbidity and 
mortality and need for transplantation in the future 
(9, 10). It is estimated that around 170 to 200 million 
individuals are living with HCV infection worldwide 
(11, 12), and there is significant geographical variation 
in the prevalence of HCV infection across countries 
and regions (1, 13). Although HCV is a hepatotropic 
virus, in some patients the primary manifestations 
of  infection  occur  outside  the  liver.  There  is  a 
growing body of evidence to support the idea that 
HCV can replicate efficiently in extrahepatic tissues 
including the PBMC. Autoimmune manifestations 
are  common  in  patients  chronically  infected  by 
HCV (14). These manifestations can be dominant, 
whereas the hepatic disease can be quiescent or mild. 
More recently, there has been growing interest in the 
relationship between HCV and Sjogren's syndrome 
(SS),  rheumatoid  arthritis  (RA),  and  systemic 
lupus  erythematosus  (SLE(15).  Depending  on  the 
pathogenic and epidemiological evidence provided 
by different studies; the extrahepatic manifestations 
of HCV infection (EHMs-HCV) can be classified 
into four categories:
1.  EHMs-HCV  characterized  by  a  very  strong 
association demonstrated by both epidemiological 
and  pathogenetic  evidence  (e.g.,  mixed 
cryoglobulinemia);
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2.  EHMs-HCV  include  disorders  for  which  the 
significant  association  with  HCV  infection  is 
supported by enough data to clearly show a higher 
prevalence of HCV than in controls but still have 
unclear pathogenic mechanisms (e.g., B-cell–derived 
non-Hodgkin's  lymphoma  [NHL],  diabetes 
mellitus, porphyria cutanea tarda, lichen planus);
3.  EHMs-HCV includes the associations for which 
the high prevalence in HCV populations could be 
due to HCV infection or confounding factors, and 
thus  these  associations  still  require  confirmation 
and a more detailed characterization with respect 
to  similar  pathologies  of  different  etiology  or 
idiopathic  nature  (e.g.,  idiopathic  pulmonary 
fibrosis, autoimmune thyroiditis, sicca syndrome, 
noncryoglobulinaemic  nephropathies  and 
glomerulonephritis, and aortic atherosclerosis);
4.  EHMs-HCV includes only anecdotal observations 
(e.g., growth hormone defficiency, chronic pruritus, 
cardiomyopathy,  psoriasis,  peripheral  or  central 
neuropathies,  chronic  polyarthritis,  rheumatoid 
arthritis, polyarthritis nodosa, behcet’s syndrome, 
poly or dermatomyositis, necrolytic acral erythema, 
and autoimmune hemolytic anemia).
1. Mixed Cryoglobulinemia
Mixed  Cryoglobulinemia  (MC)  is  the  most 
documented  and  closely  associated  disorder  with 
HCV  (16,  17).  The  prevalence  of  HCV-infected 
patients with coexisting circulating MC ranges from 
less than 10% to greater than 50%; however, overt 
vasculitis manifestations are seen in only 2% to 3% 
of these patients (18-20). This variability may represent 
geographic and population-specific factors involved in 
the development of MC, differences in the definition 
of the disease, and laboratory techniques for diagnosis. 
The disease occurs as a result of chronic immune-
system stimulation leading to B-cell clonal expansion 
and immune-complex (IgG, IgM, RF complement, 
HCV-LDL/VLDL)  production.  These  immune 
complexes will often take the form of cryoglobulins 
(21-23). Cryoglobulins are monoclonal or polyclonal 
immunoglobulins that reversibly precipitate at low 
temperatures; cryoglobulinemia occurs when these 
proteins are present in the circulation (24). Clinical 
manifestations of MC are secondary to a systemic 
immune-complex–related vasculitis involving small 
vessels.
Diagnosis of Cryoglobulinemia
Nowadays, there are no standardized criteria for the 
diagnosis of MCS. However, valuable classifications 
have been proposed by the Italian Group for the 
Study of Cryoglobulinemia (24). Diagnosis is based 
on  clinicopathological  and  laboratory  findings. 
Cryoglobulinemia may be suspected if the patient has 
positive rheumatoid factors. Clinically, asymptomatic 
serum  MC  can  be  found  in  some  individuals 
chronically infected with HCV (24, 25); a condition 
that may precede the clinical onset of the disease by 
years  or  decades.  Glomerulonephritis,  peripheral 
neuropathy,  and  generalized  vasculitis  are  the 
common complications of cryoglobulinemia (26-28).   
Palpable purpura (Figure. 1) is the most common 
clinical  finding,  occurring  in  90%  of  cases.  The 
association between MC and severe liver damage or 
steatosis has been discussed widely  (29-31). Several 
studies have shown an epidemiological association 
between MC and severe liver damage (29). However, 
the pathogenetic mechanisms of such an association 
have  not  been  clearly  identified.  The  laboratory 
work-up  of  cryoglobulinemia  vasculitis  includes 
cryoglobulin testing, quantification of total serum 
protein and immunoglobulins, complement levels, 
evaluation of serum for monoclonal gammopathy, 
RF  activity,  virological  markers  (anti-HCV 
antibodies, HCV RNA, hepatitis B virus serology, 
hepatitis B virus DNA, and others), blood chemistry, 
and  urine  analysis.  Leukocytoclastic  vasculitis, 
involving  medium-  and,  more  often,  small-sized 
blood vessels (arterioles, capillaries, and venules) is 
the typical pathological finding of involved tissues. 
Leukocytoclastic  vasculitis  is  easily  detectable  by 
means  of  skin  biopsy  of  recent  vasculitis  lesions 
(within the first 24 to 48 hours (24, 32, 33).
Figure  1.  Nonblanching  erythematosus 
papules are the notable findings of these 
palpable purpura, which are characteristic 
of the vasculitis associated with MC.
Treatment options
Treatment can eradicate HCV infection (etiologic 
therapy),  suppress  B-cell  clonal  expansion  and 
cryoglobulin production (pathogenetic therapy), or 
ameliorate symptoms (symptomatic therapy). 
Etiologic therapy
Under ideal circumstances, the treatment of MC 
aims  to  eradicate  the  HCV  infection.  Treatment Hepat Mon. 2010; 10(4): 258-269
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of MC with interferon (IFN) therapy is associated 
with  a  relatively  poor  response  (34,  35);  however, 
PEG-IFN plus RBV show better results (36, 37). The 
goal of therapy in those patients is not limited to a 
sustained virologic response; rather, patients might 
see  an  improvement  in  their  renal  manifestations 
with prolonged treatment courses. However, clinical 
improvements  are  often  transient  and  restricted 
to patients with mild to moderate disease activity 
(36-38).  Moreover,  IFN  therapy  can  induce  an 
exacerbation of various vasculitis manifestations (i.e., 
glomerulonephritis, neuropathy), and RBV, due to 
its  renal  elimination,  may  be  contraindicated  in 
patients with severe renal impairment.
Pathogenetic therapy
This  therapy  is  currently  used  when  antiviral 
therapy is not recommended. Treatment should be 
limited to the time (weeks or months) required for 
symptom remission. Several alternative therapies may 
be adopted, which include corticosteroids due to its 
anti-inflammatory and immunosuppressive actions 
(at high doses: 1 mg/kg daily or 0.5–1 g). However, 
the disadvantage of favoring the etiologic agent is 
that it can lead to increased viral replication  (39). 
Immunosuppressive drugs (e.g., Cyclophosphamide, 
Chlorambucil,  and  Azathioprine)  are  used  to 
suppress  antibody  and  cryoglobulin  production 
(40,  41).  The  most  effective  and  commonly  used 
cytotoxic drug is Cyclophosphamide, given orally at 
doses of 2 mg/kg per day. Recently; Mycophenolate 
Mofetil (1 g twice a day) can be used as a less toxic 
alternative to Cyclophosphamide for the induction 
of remission in MC vasculitis; Mycophenolic Acid is 
more selective than Cyclophosphamide in inhibiting 
lymphocyte proliferation and functions. Interestingly, 
Mycophenolic  Acid  seems  to  reduce  viremia  in 
HCV-infected  renal  or  heart-transplant  recipients 
due to its ability to inhibit inosine monophosphate 
dehydrogenase, the same target enzyme inhibited by 
RBV (42). However, data supporting this approach are 
limited and almost exclusively derived from anecdotal 
reports (43). For patients unresponsive to treatment 
with  steroids  or  other  immunosuppressants,  the 
administration  of  the  novel  immunosuppressant 
Rituximab; a chimeric monoclonal antibody directed 
against CD20 antigen on B cells, has been recently 
proposed for the pathogenetic treatment of HCV-
related MC (44, 45). By depleting B cells, Rituximab 
has the potential to reduce the development of plasma 
cells,  thereby  limiting  Cryoglobulin  production. 
Rituximab,  at  the  standard  dose  of  375  mg/m2 
weekly for 4 weeks proved to be a safe and effective 
treatment for most patients with HCV-MC, leading 
to significant clinical improvement as a consequence 
of  both  B-cell  depletion  and  decreases  in  serum 
Cryoglobulin  levels  (44-48).  Although  fever,  chills, 
nausea, vomiting, urticaria, orthostatic hypotension, 
and  bronchospasm  occur  in  more  than  80%  of 
patients,  these  side  effects  are  generally  mild  and 
limited to the infusion period. An increase in viral 
load, without significant variations in liver-function 
tests,  has  been  detected  after  rituximab  treatment 
(44) To reduce HCV replication, a combination of 
Rituximab with antiviral agents has been suggested.
Because  the  median  duration  of  the  response 
to Rituximab therapy is about 1 year, a relapse of 
cryoglobulinemic  vasculitis  may  develop  following 
treatment. Relapses are preceded by peripheral B-cell 
repletion.  It  is  unknown  whether  maintenance 
therapy  with  Rituximab  is  better  than  retreatment 
after  relapse.  Plasmapheresis  can  be  used  as  an 
effective adjuvant therapy to treat severe exacerbations 
of  cryoglobulinemic  vasculitis,  particularly  active 
cryoglobulinemic glomerulonephritis. Both traditional 
plasma exchange and double-filtration plasma exchange 
are able to markedly reduce the levels of circulating 
immune complex, especially the cryoglobulins. Oral 
Cyclophosphamide  (50  to  100  mg/day  for  2  to  6 
weeks) during the tapering of apheretic sessions can 
reinforce  the  beneficial  effect  of  plasma  exchange; 
moreover, it can prevent the rebound phenomenon 
that  may  be  observed  after  the  discontinuation  of 
aphaeresis (33).
Symptomatic Therapy
The  hypoantigenic  diet  (LAC)  diet  consists 
of  a  diet  with  reduced  content  of  alimentary 
macromolecules  with  high  antigenic  properties, 
allowing for more efficient removal of CGs by the 
reticuloendothelial  system. This  diet  can  improve 
minor  manifestations  of  the  disease  (purpura, 
arthralgias, paresthesias) and is generally prescribed 
at the initial stage of the disease (49). Colchicine, an 
anti-inflammatory  agent  with  a  relatively  selective 
effect for gouty arthritis, has been proposed for MC 
patients with mild to moderate levels of the disease. 
In an uncontrolled trial, colchicine (1 mg/day for 
6 to 48 months) improved clinical and laboratory 
variables  (particularly  cryocrit;  (50).  However,  its 
toxicity and the availability of alternative, less toxic 
agents have substantially lessened its use.
2. Lymphoproliferative disorders (LPD)
HCV-associated  LPD  can  be  observed  during 
the course of MC or in non-MC–related idiopathic 
forms (51). A recent, large-scale, retrospective cohort 
study  suggests  that  HCV  infection  confers  a  20-
30% increased risk of NHL overall (52). These results 
were confirmed in a meta-analysis by Dal Maso and 
Franceschi, which included 15 case-controlled studies Hepat Mon. 2010; 10(4): 258-269
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and 3 cohort studies and demonstrated a pooled risk 
ratio (relative risk [RR]) of 2.0 (95% CI, 1.8 to .2) 
for the cohort studies and 2.5 (95% CI, 2.1 to 3.1) 
for the case-controlled studies for the development 
of B-cell NHL in HCV-infected patients (53). The 
meta-analysis did not show differing RRs for NHL 
subtypes.  From  a  histopathological  point  of  view, 
although virtually all types of lymphoid malignancy 
can be found in patients with HCV infection, the 
strongest  association  is  with  NHL,  and  the  vast 
majority of NHL is low grade with predominantly 
extranodal  involvement.  According  to  the  REAL/
WHO  classifications,  the  most  prevalent  HCV-
associated  LPDs  are  follicular  lymphoma,  B-cell 
chronic lymphocytic leukemia or small lymphocyte 
lymphoma,  diffuse  large  B-cell  lymphoma,  and 
marginal  zone  lymphoma,  including  the  mucosa-
associated lymphoid tissue lymphoma (54). Overall, 
marginal-zone  lymphoma  appears  to  be  the  most 
frequently encountered low-grade B-cell lymphoma 
in HCV patients (55). Regarding the pathogenesis of 
the HCV-associated LPDs, the majority of studies 
pinpoint two presumable mechanisms. The first is 
indirect; specifically, by relying on the chronic nature 
of HCV infection, chronic antigenic stimulation may 
lead to an overexpression of B-cells favoring certain 
clones. This mechanism could explain the immune 
dysregulation  leading  to  autoimmunity,  MC,  and 
eventually  malignant  transformation  (56).  The 
second mechanism is direct, relying on the particular 
lymphotropism of HCV and therefore on the high 
invasion of B-cells by HCV (57). Both mechanisms 
lead  simultaneously  through  complex,  multistep, 
pathogenic  pathways.  There  may  be  genetic  and 
environmental factors that further explain the final 
steps to malignant transformation. Rearrangement 
of  the  antiapoptotic  bcl-2  gene  with  t(14;18) 
translocation  is  the  most  common  chromosomal 
translocation  in  lymphoid  cancers,  especially 
follicular  lymphoma,  a  subtype  of  NHL. Thirty-
five percent of patients with chronic HCV infection 
have evidence of the t(14;18) translocation in their 
peripheral  mononuclear  cells,  which  may  further 
contribute to lymphomagenesis  (58). Mutations in 
other oncogenes, such as c-myc, and regulators of 
apoptosis may be the important missing link to our 
understanding of lymphomagenesis in the setting of 
chronic HCV infection.
Hepatitis C Virus and Monoclonal Gammopathy
Serum  monoclonal  gammopathy  (MG)  is  an 
extrahepatic  manifestation  of  HCV  infection.  A 
prospective study by Andreone et al. found 11% of 
monoclonal bands in HCV-positive patients versus 
1%  in  HCV-negative  patients,  demonstrating  a 
significant prevalence of monoclonal gammopathy 
in  HCV-related  liver  disease  (59).  Actually,  a  few 
HCV positive patients with MG can be considered 
affected  by  myeloma  according  to  clinico-
pathological characteristics; the US Veterans Affairs 
database evaluated by Giordano et al. revealed an 
increased risk for the development of Waldenström’s 
macroglobulinemia  (hazard  ratio=2.76)  with  no 
associated increased risk of development of multiple 
myeloma in HCV patients (52).
Therapy for HCV-related LPD
Recent studies support the rationale for the use of 
antiviral therapy in the context of low-grade HCV-
positive NHL regardless of histological subtype (60-62). 
Interestingly,  in  these  studies,  there  is  a  clear 
correlation  between  HCV  viral-load  reduction 
and  clinical  response  in  LPD-infected  patients.  In 
intermediate  and  high-grade  NHL,  chemotherapy 
is  usually  necessary  and  antiviral  treatment  may 
serve  as  maintenance  therapy  after  the  completion 
of  chemotherapy  (63).  Because  chemotherapy  may 
lead to a substantial increase in the levels of viremia, 
cautious  monitoring  of  the  HCV  RNA  levels  and 
transaminases  is  important;  still,  a  consecutive 
exacerbation of the infection, making discontinuation 
of chemotherapy mandatory, is not unlikely to occure 
(63).  Regular  monitoring  of  transaminases  during 
treatment is essential because HCV-positive patients 
seem  to  experience  increased  short-term  hepatic 
toxicity  from  chemotherapy. The  use  of  rituximab 
either  in  monotherapy  or  in  combination  with 
antiviral treatment or chemotherapy or both appears 
promising (64, 65), however more studies are needed to 
define the actual role of rituximab in treatment and 
recovery.
3. HCV-associated arthritis (HCV-AR)
Rheumatologic complications of HCV infection 
are common and include MC, vasculitis, Sjogren’s 
syndrome, arthritis, and fibromyalgia (66, 67). There 
is a well-defined picture of arthritis associated with 
the presence of MC that consists of an intermittent 
mono-  or  oligoarticular,  nondestructive  arthritis 
affecting  large-  and  medium-size  joints  (66,  68). 
Joint involvement is the most frequent extrahepatic 
manifestation of HCV infection.  The HCV-associated 
rheumatic  manifestation  varies  from  2%  to  23%, 
depending on the geographic region and the design 
of the studies (69-73). HCV-AR commonly presents 
as a rheumatoid-like, symmetrical polyarthritis (SP) 
involving mainly small joints or less commonly as 
intermittent mono- or oligoarthritis in large joints 
(IMO(74,  75). The  different  diagnosis  between  SP 
and  other  polyarthritides,  especially  rheumatoid Hepat Mon. 2010; 10(4): 258-269
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renal  insufficiency.  The  majority  of  patients 
develop hypertension, often severe and difficult to 
control, and it may manifest acutely as oliguric-
acute renal failure in 5% of cases (94). The course of 
HCV-associated GN is characterized by remission 
and  phases  of  relapse.  The  long-term  outcome 
of  HCV-associated  nephropathies  remains  ill-
defined. However, the overall prognosis for patients 
with  HCV-associated  GN  is  poor  (93).  Patients 
with  HCV  infection  and  membranoproliferative 
glomerulonephritis  (MPGN)  tend  to  experience 
recurrences  of  both  conditions  following  liver 
transplantation,  and  they  have  lower  survival 
rates than do HCV-infected patients who do not 
have cryoglobulinemia or renal disease (95). In all 
patients with proteinuria, a reduction in HCV RNA 
clearance has been documented at the end of IFN 
therapy (96). The diagnosis of HCV-related MPGN 
is made by positive tests for serum HCV antibodies 
and HCV RNA. ALT levels are increased in 70% 
of  patients,  and  the  majority  have  low  serum 
concentrations  of  complementary  components 
(C1q, C4, and C3; (94). Hepatitis C virus-associated 
posttransplant glomerulopathies, both recurrent and 
de novo, can occur in kidney-transplant recipients 
with  HCV  infection,  especially  in  patients  with 
higher HCV viral loads (97). Another study found 
the prevalence of proteinuria to be greater among 
HCV-positive  kidney-transplant  recipients  (98). 
Membranoproliferative glomerulonephritis type I, 
focal and segmental glomerulosclerosis, minimal-
change  disease,  membranous  nephropathy,  renal 
thrombotic microangiopathy, and mixed essential 
cryoglobulinemia  in  kidney  transplant  recipients 
have all been associated with HCV infection (Table 2) 
(97, 98).
Table 2. Glomerular disease associated with HCV
Common types  Less common types
MPGN, with 
cryoglobulinemia





• Focal and segmental glomerulosclerosis 
• Fibrillary or immunotactoid glomerulopathy.
Treatment
For all patients, the decision to initiate treatment 
should be made after weighing the possible benefits 
and harms of therapy. The recommended therapeutic 
strategy depends on the severity of the kidney disease. For 
all patients, the same renoprotective measures (blood-
pressure-lowering  drugs  and  antiprotinuric  agents) 
commonly used in patients with chronic nephropathies 
should be used in patients with HCV-associated GN. 
Diuretics,  lipid-lowering  agents,  and  angiotensin-
converting enzyme inhibitors or angiotensin receptor 
blockers  are  potentially  beneficial  in  patients  with 
HCV-associated GN (99). In a recent meta-analysis of 
clinical, controlled trials of the two treatments (antiviral 
versus immunosuppressive) described for HCV-related 
GN, the majority of patients had cryoglobulinemic 
GN  (96). The  primary  endpoint  was  the  frequency 
of patients with a reduction of proteinuria (return of 
proteinuria to normal or a decrease of at least 50%) 
by the end of therapy. Pooling the results from this 
study demonstrated that proteinuria decreased more 
commonly  after  standard  IFN-doses  than  with 
corticosteroid therapy and the OR was 3.86 (95% CI, 
1.44; 10.33; P=0.007); however, both treatments failed 
to  improve  renal  function.  The  authors  concluded 
that the antiviral therapies were more effective than 
immunosuppressive therapy in lowering proteinuria 
levels in patients with HCV-related GN, at least in 
the short term. Therefore, the first-line treatment 
for  patients  with  mild  to  moderate  clinical  and 
histological kidney damage is antiviral therapy. In case 
of severe renal involvement (nephrotic syndrome, 
nephritic syndrome, progressive renal failure, or a 
high activity score of glomerulonephritis on light 
microscopy), the initial treatment may consist of 
sequential  administration  of  immunosuppressive 
therapies  (plasmapheresis,  corticosteroids,  and 
cyclophosphamide). Caution should be taken using 
immunosuppressive therapy in patients with HCV-
associated GN because of a concern regarding viral 
replication (100). For patients unresponsive to steroid 
and immunosuppressive therapy, preliminary data 
support the use of rituximab for the treatment of 
HCV-associated GN (101). This is a human-mouse  Figure 2. Mechanisms of HCV-induced renal injuryHepat Mon. 2010; 10(4): 258-269
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chimeric monoclonal antibody that selectively depletes 
B-cell by binding to CD20 cell surface antigen (102). 
It  has  been  suggested  that  rituximab  has  a  marked 
antiproteinuric  effect  through  interference  with 
monoclonal IgM production, cryoglobulin synthesis, 
and  renal  deposition  of  immune  complexes  (ICs). 
Recent data notes that Rituximab combined with Peg-
IFNα/ribavirin  is  well-tolerated  and  more  effective 
than  Peg-IFNα/ribavirin  in  HCV-MC.  In  a  recent 
prospective cohort study of 38 HCV-MC patients who 
received a combination of Rituximab (375mg/m² once 
a week for 1 month) followed by weekly Peg-IFNα (2a, 
180mcg or 2b, 1.5mcg/kg) plus ribavirin (600-1,200 
mg) daily for 48 weeks were compared to 55 HCV-MC 
patients who received the same Peg-IFNα and ribavirin 
treatments. Compared with Peg-IFNα and ribavirin, 
patients who received rituximab plus Peg-IFNα and 
ribavirin had a shorter time to clinical remission, better 
renal-response rates, and a high tolerance for treatment 
with no worsening of HCV RNA under rituximab 
(103). Another very recent, long-term trial confirmed 
these results, which may last for over 3 years (104).
5. HCV and Thrombocytopenia
Several studies have shown that thrombocytopenia 
is frequently observed in patients with chronic hepatitis 
C infection (69, 105-108), and a variety of pathogenic 
mechanisms  that  are  implicated  in  this  abnormal 
finding are portal hypertension and hypersplenism in 
the cirrhosis stage, autoimmune reaction to platelets, 
and direct infection of platelet and megakaryocytes 
by HCV infection. This may be a sign of extrahepatic 
manifestation of chronic hepatitis C (109). In cirrhotic 
patients,  sequestration  of  platelets  in  the  enlarged 
spleen  secondary  to  portal  hypertension  can  cause 
thrombocytopenia (105). However, thrombocytopenia 
also occurs in patients with chronic hepatitis C without 
cirrhosis. Another mechanism is autoimmune reaction 
to  platelets  (110,  111).  Some  reports  indicated  that 
HCV infection may reflect the expression of platelets-
associated  immunoglobulin  G(PAIgG),  which  can 
lead to platelets destruction by the reticulo-endothelial 
system  (112,  113).  In  addition,  several  studies  have 
suggested that HCV may have a direct pathogenic role 
in the process leading to thrombocytopenia (105, 114). 
The incidence of mild thrombocytopenia (defined as 
a platelet count under 150,000/μl) is between 41% 
and 50% in patients with HCV infection, whereas 
severe thrombocytopenia (defined as a platelet count 
under 50,000/μl) is less common (105, 115). 
6. Cutaneous Manifestations of HCV
In  addition  to  MC-related  purpura,  HCV 
infection  also  has  been  associated  with  several 
cutaneous disorders as noted below. 
Pruritus
Pruritus  is  a  presenting  symptom  in  20%  of 
patients (116). Although, the pathogenesis is uncertain, 
both peripheral (increased plasma level of bile salts) 
and central mechanisms (increased plasma level of 
opioids) have been proposed (116). The combination 
of  both  bile-salt-lowering  and  opioid-antagonist 
strategies appears reasonable in the management of 
pruritus  of  cholestasis;  treatment  options  include 
topical  antipruritics,  systemic  antihistamines, 
rifampin, naloxone or naltrexone, and ultraviolet B 
phototherapy (116).
Porphyria Cutanea Tarda (PCT)
PCT  is  a  photosensitivity  disorder  caused  by  a 
decrease in functional uropophryinogen decarboxylase 
(UROD) and an increase in circulating porphyrins. The 
prevalence of HCV infection in patients with porphyria 
is high, ranging from 40% to 50% (Figure 3) (117). 
HCV does not seem to induce alteration of porphyrin 
metabolism,  although  it  may  induce  the  disease  in 
genetically predisposed individuals. Meanwhile, some 
authors suggest that PCT might be related to HCV-
induced hepatic iron overload (117). The highest rates 
of PCT have been observed in patients with HCV-
related  liver  cirrhosis,  suggesting  that  cirrhosis  may 
play a role in its development. Antiviral therapy seems 
to ameliorate cutaneous lesions, but there is still no 
randomized clinical trial (117).
Lichen Planus (LP)
HCV has been implicated in triggering LP (118). 
In a recent meta-analysis, LP patients were observed 
to  have  significantly  higher  risk  of  being  HCV 
seropositive (odds ratio 4.85; 95% CI 3.58-6.56) than 
controls. A similar odds ratio of having lichen planus 
was found among HCV patients (4.47; 95% CI 1.84-
10.86). Subanalyses indicated that the variability in the 
association between HCV and lichen planus seemed 
only partial and dependent on geographic effect Studies. 
Figure 3. Erosions, crust, and blisters are evident 
on the hands of this patient with PCT.Hepat Mon. 2010; 10(4): 258-269
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(118). Data from Egypt reveal that the prevalence of 
LP among CHC patients is around 4%  (119). Data 
suggest that skin and mucosal lesions may be caused by 
direct action of the virus or immunological response, 
especially when erosive oral lesions are present, and 
recently  HCV-induced  insulin  resistance  has  been 
implicated in the pathogenesis of LP (118, 120). The skin 
and the oral cavity are easy to observe, so the presence 
of LP can be potentially used as a potential marker of 
HCV in asymptomatic patients (Figure 4) (121). 
Figure. 4. The polygonal purple papules 
of LP are evident on the forearms of a 
patient with HCV.
Treatment
LP is associated with a variable response to IFN 
treatment, and both improvement and exacerbation 
of symptoms have been reported. The uses of steroids, 
either topical or injectable, are also used in managing 
the symptoms (120).
Link between HCV and other clinical disorders
7. Sicca syndrome
Sjögren’s syndrome (SS) is an autoimmune disease 
that  involves  the  exocrine  glands  and  generally 
induces xerostomia and xeroftalmia (sicca syndrome) 
due  to  an  involvement  of  salivary  and  lachrymal 
glands in the presence of immunological alterations 
represented  by  antinuclear  autoantibodies  and 
antiepithelial  neutrophil-activating  peptide  (ANA, 
SSA/Ro, SSB/La). In the absence of an associated 
systemic autoimmune disease, patients with similar 
manifestations can be defined as affected by primary 
SS. The clinical spectrum of the syndrome ranges from 
an organ-specific autoimmune disease to a systemic 
process with different manifestations. SS is recognized 
in large portions of MC patients (122, 123), and was 
also  observed  in  CHC  patients  by  Haddad  et  al. 
in 1992 (124). In a recent cohort from Egypt, SS’s 
prevalence was reported to be around 9% (73). This 
syndrome  closely  resembles  primary  SS;  however, 
it typically lacks ANA, SSA/Ro, and SSB/La. The 
pathogenic  role  of  HCV  infection  in  SS  remains 
an issue of debate (125). It has been proposed that 
HCV infection is a criterion to rule out a primary 
diagnosis of SS, especially if cryoglobulinemia and 
hypocomplementemia are present and anti-SSA/Ro 
antibodies are absent (126, 127).
8. Idiopathic pulmonary fibrosis (IPF) 
A pathogenic link between HCV infection and 
IPF has been suggested by the higher frequency of 
HCV markers in patients with IPF (128, 129). Whether 
CHC  is  linked  to  pulmonary  fibrosis  directly  or 
indirectly  through  underlying  cryoglobulinaemia 
and vasculitis remains issue of discussion (130).
9. Cardiomyopathy and atherosclerosis
A causal relationship with HCV infection has been 
suspected for several myocardial impairments, including 
dilated cardiomyopathy, hypertrophic cardiomyopathy, 
and chronic myocarditis. The pathogeneses of these 
HCV-associated  myocardial  impairments  probably 
rely on autoimmune phenomena with the particular 
involvement of the human major histocompatibility 
(MHC)  class  II  antigen  (131).  Moreover,  the  recent 
determination of a significantly higher prevalence of 
carotid or coronary artery atherosclerosis in patients 
with  HCV  infection  (132,  133)  is  noteworthy.  The 
recent  finding  of  HCV  RNA  sequences  in  plaque 
tissue strongly suggests an active local infection. This 
in turn makes it conceivable that the virus may exert 
local action in carotid atherosclerosis (134). 
10. Neuropathy 
HCV-neuropathy  presents  with  peripheral 
neuropathy  that  involves  the  legs  and  is  typically 
very painful, with progression to muscle weakness in 
some patients. The disorder results from immune-
complex deposits within the vasa nervorum of the 
peripheral nerves leading to vasculitis (135). Antiviral 
therapy should be applied cautiously in the presence 
of  neuropathy.  Although  cases  of  HCV-related 
peripheral neuropathy responsive to antiviral therapy 
with IFNα and ribavirin have been described (136), 
several authors have reported an aggravation of pre-
existing  MC-related  neuropathy  or  even  de  novo 
occurrence of demyelinating polyneuropathy during 
IFN-α or PEG-IFN-α treatment (137). Therefore, it 
is presumable that genetic susceptibility and other 
idiosyncratic factors may influence the response of 
the HCV-associated neuropathy to IFNα, making 
close monitoring of the course of this EHM during 
IFNα treatment indispensable.
11. Thyroid and HCV
Autoimmune  thyroid  diseases  (AITDs)  are 
complex diseases that develop as a result of interactions Hepat Mon. 2010; 10(4): 258-269
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between  genetic,  epigenetic,  and  environmental 
factors.  Significant  progress  has  been  made  in  our 
understanding of the genetic and environmental triggers 
contributing to AITD. The high prevalence of AITDs 
has  been  reported  in  HCV-infected  patients  before 
and after IFNα therapy (138). Two well-documented 
environmental triggers of AITD, HCV infection and 
IFNα therapy, should be given more attention in the 
field (139). Chronic HCV infection has been shown to 
be associated with an increased incidence of clinical 
and  subclinical  autoimmune  thyroiditis  (i.e.,  the 
presence of thyroid antibodies in euthyroid subjects). 
The pattern of thyroid disorders observed in HCV 
infection is characterized by the presence of increased 
circulating antithyroid peroxidase antibodies (AbTPO) 
and an increased risk of hypothyroidism in AbTPO-
positive subjects (109, 140). The Autoantibodies against 
internal organs such as the thyroid are common before 
therapy  with  IFNα  (141). In some cases, antibodies 
against IFN appear after IFN therapy with in HCV-
infected patients (142). Moreover, IFNα  therapy for 
chronic HCV infection is associated with subclinical 
or clinical thyroiditis in up to 40% of cases, which can 
be  autoimmune  or  nonautoimmune  thyroiditis.  In 
some cases, IFN induced thyroiditis (IIT) in chronic 
HCV patients may result in severe symptomatology 
necessitating the discontinuation of therapy. Although 
the epidemiology and clinical presentation of HCV- and 
IFN-induced thyroiditis have been well-characterized, 
the  mechanisms  causing  these  conditions  are  still 
poorly understood.
Treatment:  In  cases  of  symptomatic 
hyperthyroidism,  discontinuation  of  therapy  is 
recommended. In hypothyroidism, adding thyroid 
hormone  can  alleviate  the  symptoms,  making  it 
possible  to  continue  therapy.  Thyroid-function 
tests should be provided every 3 months during the 
therapy.
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